Precision NanoSystems Expands GMP Biomanufacturing Center

PNI expands global headquarters with a new 75,000-square-foot facility, which will include multiple GMP suites for manufacturing RNA therapeutics and vaccines.

On August 11, 2021, Precision NanoSystems (PNI) announced an expansion of its global headquarters with a 75,000-ft2 facility. The facility, located in Vancouver, British Columbia, Canada is currently under construction and expected to be completed in the fourth quarter of 2022.

The company’s new genetic medicine good manufacturing practice biomanufacturing center will be housed at this site, which will support drug development through clinical phases as well as Canada’s pandemic efforts by offering manufacturing for RNA vaccines. In addition, PNI intends to expand capabilities into clinical manufacturing of RNA vaccines and therapeutics.

The biomanufacturing center was partially funded with CA$25.1 million (US$20.1 million) from Canada’s Strategic Innovation Fund.

Source: Precision NanoSystems